3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
18
Neoplasms
11
Venous Thrombosis
9
Pulmonary Embolism
9
Thrombosis
5
Multiple Myeloma
4
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Upper Extremity Deep Vein Thrombosis
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Mesenteric Ischemia
1
Leukemia
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Interventions
Gemcitabine
112
Cisplatin
76
Oxaliplatin
44
pembrolizumab
34
Fluorouracil
32
Capecitabine
30
durvalumab
27
Leucovorin
26
lenvatinib
23
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Nivolumab
12
Biopsy
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
Drug Therapy
11
pemigatinib
10
apatinib
10
Taxes
10
Floxuridine
10
130-nm albumin-bound paclitaxel
10
Radiotherapy
9
Bevacizumab
9
Platinum
8
Folfox protocol
8
Carboplatin
8
1,2-diaminocyclohexaneplatinum II citrate
8
tremelimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cholangiocarcinoma
×
apixaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled